Host immunity influences disease progression and antiviral efficacy in humans infected with hepatitis B virus

Expert Review of Gastroenterology and Hepatology

Volumn 3, Issue 5, 2009, Pages 499-512

  Wang, Fu Sheng ^a   Zhang, Zheng ^a  

^a BEIJING 302 HOSPITAL   (China)

Author keywords

Antiviral therapy; Disease progression; Hepatitis B virus; Host immunity; Immune therapy

Indexed keywords

ADEFOVIR DIPIVOXIL; ADENINE NUCLEOTIDE DERIVATIVE; ALPHA INTERFERON; DENDRITIC CELL VACCINE; EMTRICITABINE; GENE PRODUCT; HEPATITIS B VIRUS X PROTEIN; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; HLA A2 ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 12; LAMIVUDINE; PEGINTERFERON; PROGRAMMED CELL DEATH 1; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; VIRUS DNA;

ACUTE ON CHRONIC LIVER FAILURE; ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; ANTIVIRAL THERAPY; APOPTOSIS; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHRONIC HEPATITIS; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; HEPATITIS B; HUMAN; HUMORAL IMMUNITY; IMMUNITY; IMMUNOMODULATION; IMMUNOTHERAPY; INNATE IMMUNITY; LIVER CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LYMPHOCYTE FUNCTION; LYMPHOCYTIC INFILTRATION; MEMORY T LYMPHOCYTE; NATURAL KILLER CELL; NATURAL KILLER T CELL; PLASMACYTOID DENDRITIC CELL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; SEROCONVERSION; T CELL DEPLETION; VIRION; VIRUS INHIBITION; VIRUS REPLICATION;

ACUTE DISEASE; ADAPTIVE IMMUNITY; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IMMUNITY, INNATE; IMMUNOLOGIC FACTORS; LIVER CIRRHOSIS; LIVER NEOPLASMS; TREATMENT OUTCOME;

EID: 70449724811     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/egh.09.50     Document Type: Review

References (124)

1. Lee WM. Hepatitis B virus infection. N. Engl. J. Med. 337, 1733-1745 (1997).
2. Ganem D, Prince AM. Hepatitis B virus infection - natural history and clinical consequences. N. Engl. J. Med. 350, 1118-1129 (2004). (Pubitemid 38298992)
3. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 45, 507-539 (2007).
4. Dienstag JL. Hepatitis B virus infection. N. Engl. J. Med. 359, 1486-1500 (2008).
5. Blumberg BS, Alter HJ, Visnich S. A "new" antigen in leukemia sera. JAMA 191, 541-546 (1965).
6. Wang FS. Clinical immune characterization of hepatitis B virus infection and implications for immune intervention: progress and challenges. Hepatol. Res. 37(Suppl. 3), S339-S346 (2007).
7. Chang JJ, Lewin SR. Immunopathogenesis of hepatitis B virus infection. Immunol. Cell Biol. 85, 16-23 (2007).
8. Tan AT, Koh S, Goh V, Bertoletti A. Understanding the immunopathogenesis of chronic hepatitis B virus: an Asian prospective. J. Gastroenterol. Hepatol. 23, 833-843 (2008). (Pubitemid 351806581)
9. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat. Rev. Immunol. 5, 215-229 (2005). •• Excellent and updated review that includes virological and immunological novel concepts regarding hepatitis B virus (HBV) infection.
10. Jung MC, Pape GR. Immunology of hepatitis B infection. Lancet Infect. Dis. 2, 43-50 (2002).
11. Lee WM. Acute liver failure. N. Engl. J. Med. 329, 1862-1872 (1993).
12. Torbenson M, Thomas DL. Occult hepatitis B. Lancet Infect. Dis. 2, 479-486 (2002).
13. Murray JM, Wieland SF, Purcell RH, Chisari FV. Dynamics of hepatitis B virus clearance in chimpanzees. Proc. Natl Acad. Sci. USA 102, 17780-17785 (2005).
14. Guidotti LG, Rochford R, Chung J et al. Viral clearance without destruction of infected cells during acute HBV infection. Science 284, 825-829 (1999). (Pubitemid 29291352)
15. Webster GJ, Reignat S, Maini MK et al. Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. Hepatology 32, 1117-1124 (2000). • First paper to describe innate and adaptive immune responses in the incubation phase of acute HBV infection. (Pubitemid 30808439)
16. Fisicaro P, Valdatta C, Boni C et al. Early kinetics of innate and adaptive immune responses during hepatitis B virus infection. Gut 58(7), 974-982 (2009).
17. Szabo G, Mandrekar P, Dolganiuc A. Innate immune response and hepatic inflammation. Semin. Liver Dis. 27, 339-350 (2007). (Pubitemid 350071835)
18. Boehme KW, Compton T. Innate sensing of viruses by Toll-like receptors. J. Virol. 78, 7867-7873 (2004). (Pubitemid 38944272)
19. Wieland S, Thimme R, Purcell RH, Chisari FV. Genomic ana lysis of the host response to hepatitis B virus infection. Proc. Natl Acad. Sci. USA 101, 6669-6674 (2004). (Pubitemid 38586032)
20. Wieland SF, Guidotti LG, Chisari FV. Intrahepatic induction of α/β interferon eliminates viral RNA-containing capsids in hepatitis B virus transgenic mice. J. Virol. 74, 4165-4173 (2000).
21. Wu J, Meng Z, Jiang M et al. Hepatitis B virus suppresses Toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells. Hepatology 49, 1132-1140 (2009).
22. Isogawa M, Robek MD, Furuichi Y, Chisari FV. Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J. Virol. 79, 7269-7272 (2005). (Pubitemid 40677357)
23. Wu J, Lu M, Meng Z et al. Toll-like receptor-mediated control of HBV replication by nonparenchymal liver cells in mice. Hepatology 46, 1769-1778 (2007).
24. Guo H, Jiang D, Ma D et al. Activation of pattern recognition receptor-mediated innate immunity inhibits the replication of hepatitis B virus in human hepatocyte-derived cells. J. Virol. 83, 847-858 (2009).
25. Visvanathan K, Skinner NA, Thompson AJ et al. Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein. Hepatology 45, 102-110 (2007). (Pubitemid 46150869)
26. McClary H, Koch R, Chisari FV, Guidotti LG. Relative sensitivity of hepatitis B virus and other hepatotropic viruses to the antiviral effects of cytokines. J. Virol. 74, 2255-2264 (2000). (Pubitemid 30091480)
27. Pasquetto V, Wieland SF, Uprichard SL, Tripodi M, Chisari FV. Cytokine-sensitive replication of hepatitis B virus in immortalized mouse hepatocyte cultures. J. Virol. 76, 5646-5653 (2002). (Pubitemid 34517915)
28. Guidotti LG, Ishikawa T, Hobbs MV et al. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 4, 25-36 (1996). (Pubitemid 26054933)
29. Racanelli V, Rehermann B. The liver as an immunological organ. Hepatology 43, S54-S62 (2006).
30. Karre K. Natural killer cell recognition of missing self. Nat. Immunol. 9, 477-480 (2008). (Pubitemid 351560515)
31. Kakimi K, Guidotti LG, Koezuka Y, Chisari FV. Natural killer T cell activation inhibits hepatitis B virus replication in vivo. J. Exp. Med. 192, 921-930 (2000). (Pubitemid 30765686)
32. Kakimi K, Lane TE, Wieland S et al. Blocking chemokine responsive to γ-2/ interferon (IFN)-γ inducible protein and monokine induced by IFN-γ activity in vivo reduces the pathogenetic but not the antiviral potential of hepatitis B virus-specific cytotoxic T lymphocytes. J. Exp. Med. 194, 1755-1766 (2001). (Pubitemid 34028655)
33. Kimura K, Kakimi K, Wieland S, Guidotti LG, Chisari FV. Activated intrahepatic antigen-presenting cells inhibit hepatitis B virus replication in the liver of transgenic mice. J. Immunol. 169, 5188-5195 (2002). (Pubitemid 35217189)
34. Liu YJ. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu. Rev. Immunol. 23, 275-306 (2005).
35. Kingham TP, Chaudhry UI, Plitas G et al. Murine liver plasmacytoid dendritic cells become potent immunostimulatory cells after Flt-3 ligand expansion. Hepatology 45, 445-454 (2007). (Pubitemid 46374601)
36. Duan XZ, Zhuang H, Wang M et al. Decreased numbers and impaired function of circulating dendritic cell subsets in patients with chronic hepatitis B infection (R2). J. Gastroenterol. Hepatol. 20, 234-242 (2005). (Pubitemid 40343275)
37. Ulsenheimer A, Gerlach JT, Jung MC et al. Plasmacytoid dendritic cells in acute and chronic hepatitis C virus infection. Hepatology 41, 643-651 (2005). (Pubitemid 40292058)
38. Penna A, Artini M, Cavalli A et al. Long-lasting memory T cell responses following self-limited acute hepatitis B. J. Clin. Invest. 98, 1185-1194 (1996). (Pubitemid 26299932)
39. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 cells. Annu. Rev. Immunol. 27, 485-517 (2009).
40. + T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J. Virol. 77, 68-76 (2003).
41. + T cells identifies functionally and phenotypically defined memory T cells during acute resolving hepatitis B virus infection. J. Virol. 80, 3532-3540 (2006).
42. + lymphocytes share the same effector-memory phenotype but exhibit functional differences in acute hepatitis B and C. J. Virol. 76, 12423-12434 (2002).
43. Wherry EJ, Ahmed R. Memory CD8 T-cell differentiation during viral infection. J. Virol. 78, 5535-5545 (2004). (Pubitemid 38661640)
44. Zhang Z, Zhang JY, Wherry EJ et al. Dynamic programmed death 1 expression by virus-specific CD8 T cells correlates with the outcome of acute hepatitis B. Gastroenterology 134, 1938-1949 (2008). • One of the first articles to define the dynamics of programmed cell death (PD)-1 expression associated with the outcome of acute HBV infection.
45. Zhang Z, Jin B, Zhang JY et al. Dynamic decrease in PD-1 expression correlates with HBV-specific memory CD8 T-cell development in acute self-limited hepatitis B patients. J. Hepatol. 50, 1163-1173 (2009). • One of the first articles to define the dynamics of PD-1 expression associated with the outcome of acute HBV infection.
46. + T cell effector functions after antigen recognition in the liver. Immunity 23, 53-63 (2005).
47. + T lymphocytes in the liver. J. Immunol. 178, 2714-2720 (2007).
48. Zerbini A, Pilli M, Boni C et al. The characteristics of the cell-mediated immune response identify different profiles of occult hepatitis B virus infection. Gastroenterology 134, 1470-1481 (2008). • Describes, for the first time, the properties of the T-cell-mediated immune response in occult HBV infection. (Pubitemid 351615362)
49. Oliviero B, Varchetta S, Paudice E et al. Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections. Gastroenterology 137(3), 1151-1160 (2009).
50. Dunn C, Brunetto M, Reynolds G et al. Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. J. Exp. Med. 204, 667-680 (2007). • Defines the role of natural killer cells in the liver injury during chronic HBV infection. (Pubitemid 46457088)
51. Du J, Liang X, Liu Y et al. Hepatitis B virus core protein inhibits TRAIL-induced apoptosis of hepatocytes by blocking DR5 expression. Cell Death Differ. 16, 219-229 (2009).
52. Crispe IN. Hepatic T cells and liver tolerance. Nat. Rev. Immunol. 3, 51-62 (2003). •• Useful paper describing the association between the immune microenvironment and immune tolerance in the liver.
53. Lau AH, Thomson AW. Dendritic cells and immune regulation in the liver. Gut 52, 307-314 (2003).
54. Goddard S, Youster J, Morgan E, Adams DH. Interleukin-10 secretion differentiates dendritic cells from human liver and skin. Am. J. Pathol. 164, 511-519 (2004). (Pubitemid 38364667)
55. Kunitani H, Shimizu Y, Murata H, Higuchi K, Watanabe A. Phenotypic ana lysis of circulating and intrahepatic dendritic cell subsets in patients with chronic liver diseases. J. Hepatol. 36, 734-741 (2002). (Pubitemid 35177401)
56. Nattermann J, Zimmermann H, Iwan A et al. Hepatitis C virus E2 and CD81 interaction may be associated with altered trafficking of dendritic cells in chronic hepatitis C. Hepatology 44, 945-954 (2006). (Pubitemid 46489559)
57. Tanimoto K, Akbar SM, Michitaka K, Horiike N, Onji M. Antigen-presenting cells at the liver tissue in patients with chronic viral liver diseases: CD83-positive mature dendritic cells at the vicinity of focal and confluent necrosis. Hepatol. Res. 21, 117-125 (2001). (Pubitemid 32899082)
58. Zhang Z, Chen D, Yao J et al. Increased infiltration of intrahepatic DC subsets closely correlate with viral control and liver injury in immune active pediatric patients with chronic hepatitis B. Clin. Immunol. 122, 173-180 (2007). (Pubitemid 46073893)
59. Zhang Z, Zou ZS, Fu JL et al. Severe dendritic cell perturbation is actively involved in the pathogenesis of acute-onchronic hepatitis B liver failure. J. Hepatol. 49, 396-406 (2008).
60. + cells in liver damage and viral control during persistent hepatitis B virus infection. J. Exp. Med. 191, 1269-1280 (2000).
61. Reignat S, Webster GJ, Brown D et al. Escaping high viral load exhaustion: CD8 cells with altered tetramer binding in chronic hepatitis B virus infection. J. Exp. Med. 195, 1089-1101 (2002). (Pubitemid 34517136)
62. Lopes AR, Kellam P, Das A et al. Bim-mediated deletion of antigen-specific CD8 T cells in patients unable to control HBV infection. J. Clin. Invest. 118, 1835-1845 (2008). • Provides explanations for HBV-specific CD8 T-cell depletion in chronic HBV infection.
63. Boni C, Fisicaro P, Valdatta C et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J. Virol. 81, 4215-4225 (2007). (Pubitemid 46586915)
64. Duan XZ, Wang M, Li HW et al. Decreased frequency and function of circulating plasmocytoid dendritic cells (pDC) in hepatitis B virus infected humans. J. Clin. Immunol. 24, 637-646 (2004). (Pubitemid 40933115)
65. Zheng BJ, Zhou J, Qu D et al. Selective functional deficit in dendritic cell - T cell interaction is a crucial mechanism in chronic hepatitis B virus infection. J. Viral Hepat. 11, 217-224 (2004). (Pubitemid 38658446)
66. van der Molen RG, Sprengers D, Binda RS et al. Functional impairment of myeloid and plasmacytoid dendritic cells of patients with chronic hepatitis B. Hepatology 40, 738-746 (2004). (Pubitemid 39265597)
67. Stoop JN, van der Molen RG, Baan CC et al. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology 41, 771-778 (2005).
68. + regulatory T cells in patients with hepatitis B virus infection. J. Virol. 79, 3322-3328 (2005).
69. Stoop JN, Woltman AM, Biesta PJ et al. Tumor necrosis factor a inhibits the suppressive effect of regulatory T cells on the hepatitis B virus-specific immune response. Hepatology 46, 699-705 (2007).
70. + regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J. Immunol. 177, 739-747 (2006).
71. Barboza L, Salmen S, Goncalves L et al. Antigen-induced regulatory T cells in HBV chronically infected patients. Virology 368, 41-49 (2007). (Pubitemid 47610682)
72. Chen L, Zhang Z, Chen W et al. B7-H1 up-regulation on myeloid dendritic cells significantly suppresses T cell immune function in patients with chronic hepatitis B. J. Immunol. 178, 6634-6641 (2007). (Pubitemid 46717448)
73. Chang JJ, Thompson AJ, Visvanathan K et al. The phenotype of hepatitis B virus-specific T cells differ in the liver and blood in chronic hepatitis B virus infection. Hepatology 46, 1332-1340 (2007). (Pubitemid 350155514)
74. Das A, Hoare M, Davies N et al. Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection. J. Exp. Med. 205, 2111-2124 (2008).
75. Urbani S, Boni C, Amadei B et al. Acute phase HBV-specific T cell responses associated with HBV persistence after HBV/HCV coinfection. Hepatology 41, 826-831 (2005). (Pubitemid 40462945)
76. Mackay IR. Autoimmune diseases of the liver, autoimmune hepatitis and primary biliary cirrhosis: unfinished business. Hepatol. Res. 37(Suppl. 3), S357-S364 (2007).
77. Huang J, Kwong J, Sun EC, Liang TJ. Proteasome complex as a potential cellular target of hepatitis B virus X protein. J. Virol. 70, 5582-5591 (1996). (Pubitemid 26240735)
78. Bouchard MJ, Schneider RJ. The enigmatic X gene of hepatitis B virus. J. Virol. 78, 12725-12734 (2004).
79. Clippinger AJ, Gearhart TL, Bouchard MJ. Hepatitis B virus X protein modulates apoptosis in primary rat hepatocytes by regulating both NF-κB and the mitochondrial permeability transition pore. J. Virol. 83, 4718-4731 (2009).
80. Clippinger AJ, Bouchard MJ. Hepatitis B virus HBx protein localizes to mitochondria in primary rat hepatocytes and modulates mitochondrial membrane potential. J. Virol. 82, 6798-6811 (2008).
81. Milich D, Liang TJ. Exploring the biological basis of hepatitis B e antigen in hepatitis B virus infection. Hepatology 38, 1075-1086 (2003). (Pubitemid 37314815)
82. Lee BO, Tucker A, Frelin L et al. Interaction of the hepatitis B core antigen and the innate immune system. J. Immunol. 182, 6670-6681 (2009).
83. Rossol S, Marinos G, Carucci P et al. Interleukin-12 induction of Th1 cytokines is important for viral clearance in chronic hepatitis B. J. Clin. Invest. 99, 3025-3033 (1997). • Indicated, for the first time, that a IFN-a therapy-induced immune response is key to clear the virus in vivo.
84. Untergasser A, Zedler U, Langenkamp A et al. Dendritic cells take up viral antigens but do not support the early steps of hepatitis B virus infection. Hepatology 43, 539-547 (2006).
85. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270, 1189-1192 (1995).
86. + T cells results in antigen-specific T-cell tolerance. Nat. Med. 6, 1348-1354 (2000).
87. Bertoletti A, Sette A, Chisari FV et al. Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells. Nature 369, 407-410 (1994). (Pubitemid 24184055)
88. Bertoletti A, Costanzo A, Chisari FV et al. Cytotoxic T lymphocyte response to a wild type hepatitis B virus epitope in patients chronically infected by variant viruses carrying substitutions within the epitope. J. Exp. Med. 180, 933-943 (1994). (Pubitemid 24256606)
89. Liu HG, Fan ZP, Chen WW et al. A mutant HBs antigen (HBsAg)183-191 epitope elicits specific cytotoxic T lymphocytes in acute hepatitis B patients. Clin. Exp. Immunol. 151, 441-447 (2008).
90. Liu HG, Chen WW, Fan ZP et al. The high prevalence of the I27 mutant HBcAg18-27 epitope in Chinese HBV-infected patients and its cross-reactivity with the V27 prototype epitope. Clin. Immunol. 125, 337-345 (2007).
91. Leifeld L, Cheng S, Ramakers J et al. Imbalanced intrahepatic expression of interleukin 12, interferon γ, and interleukin 10 in fulminant hepatitis B. Hepatology 36, 1001-1008 (2002).
92. Antoniades CG, Berry PA, Davies ET et al. Reduced monocyte HLA-DR expression: a novel biomarker of disease severity and outcome in acetaminophen-induced acute liver failure. Hepatology 44, 34-43 (2006).
93. Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J. Biol. Chem. 275, 2247-2250 (2000).
94. Jo M, Kim TH, Seol DW et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat. Med. 6, 564-567 (2000). (Pubitemid 30305907)
95. Rivero M, Crespo J, Fabrega E et al. Apoptosis mediated by the Fas system in the fulminant hepatitis by hepatitis B virus. J. Viral Hepat. 9, 107-113 (2002). (Pubitemid 36002473)
96. Lee JY, Chae DW, Kim SM et al. Expression of FasL and perforin/granzyme B mRNA in chronic hepatitis B virus infection. J. Viral Hepat. 11, 130-135 (2004).
97. Ramm GA, Shepherd RW, Hoskins AC et al. Fibrogenesis in pediatric cholestatic liver disease: role of taurocholate and hepatocyte-derived monocyte chemotaxis protein-1 in hepatic stellate cell recruitment. Hepatology 49, 533-544 (2009).
98. Fu J, Xu D, Liu Z et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 132, 2328-2339 (2007). (Pubitemid 46890865)
99. Zhang JP, Yan J, Xu J et al. Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J. Hepatol. 50, 980-989 (2009).
100. Schwartz M, Roayaie S, Konstadoulakis M. Strategies for the management of hepatocellular carcinoma. Nat. Clin. Pract. Oncol. 4, 424-432 (2007).
101. Budhu A, Forgues M, Ye QH et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 10, 99-111 (2006). (Pubitemid 44202603)
102. Perrillo R. Benefits and risks of interferon therapy for hepatitis B. Hepatology 49, S103-S111 (2009).
103. Janssen HL, van Zonneveld M, Senturk H et al. Pegylated interferon α-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 365, 123-129 (2005). (Pubitemid 40091801)
104. Lau GK, Piratvisuth T, Luo KX et al. Peginterferon α-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 352, 2682-2695 (2005). (Pubitemid 41007823)
105. Marcellin P, Lau GK, Bonino F et al. Peginterferon α-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 351, 1206-1217 (2004). (Pubitemid 39296307)
106. Boni C, Bertoletti A, Penna A et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J. Clin. Invest. 102, 968-975 (1998). (Pubitemid 28419565)
107. Boni C, Penna A, Bertoletti A et al. Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. J. Hepatol. 39, 595-605 (2003). (Pubitemid 37204661)
108. van der Molen RG, Sprengers D, Biesta PJ, Kusters JG, Janssen HL. Favorable effect of adefovir on the number and functionality of myeloid dendritic cells of patients with chronic HBV. Hepatology 44, 907-914 (2006). (Pubitemid 46489555)
109. Stoop JN, van der Molen RG, Kuipers EJ, Kusters JG, Janssen HL. Inhibition of viral replication reduces regulatory T cells and enhances the antiviral immune response in chronic hepatitis B. Virology 361, 141-148 (2007).
110. Evans A, Riva A, Cooksley H et al. Programmed death 1 expression during antiviral treatment of chronic hepatitis B: impact of hepatitis B e-antigen seroconversion. Hepatology 48, 759-769 (2008).
111. + T-lymphocyte response is important for therapy-induced viral clearance in chronic hepatitis B infection. J. Hepatol. 43, 45-52 (2005).
112. Carotenuto P, van Riel D, Artsen A et al. Antiviral treatment with a interferon up-regulates CD14 on liver macrophages and its soluble form in patients with chronic hepatitis B. Antimicrob. Agents Chemother. 49, 590-599 (2005). (Pubitemid 40175667)
113. Gregorek H, Dzierzanowska-Fangrat K, Woynarowski M et al. Persistence of HBV-DNA in children with chronic hepatitis B who seroconverted to anti-HBs antibodies after interferon-α therapy: correlation with specific IgG subclass responses to HBsAg. J. Hepatol. 42, 486-490 (2005). (Pubitemid 40342926)
114. Zhang Z, Zhang H, Chen D et al. Response to interferon-α treatment correlates with recovery of blood plasmacytoid dendritic cells in children with chronic hepatitis B. J. Hepatol. 47, 751-759 (2007). (Pubitemid 350051116)
115. Andersson KL, Chung RT. Monitoring during and after antiviral therapy for hepatitis B. Hepatology 49, S166-S173 (2009).
116. Akbar SM, Horiike N, Onji M. Immune therapy including dendritic cell based therapy in chronic hepatitis B virus infection. World J. Gastroenterol. 12, 2876-2883 (2006). (Pubitemid 43805457)
117. Shi M, Fu J, Shi F et al. Transfusion of autologous cytokine-induced killer cells inhibits viral replication in patients with chronic hepatitis B virus infection. Clin. Immunol. 132, 43-54 (2009).
118. Kuo TK, Hung SP, Chuang CH et al. Stem cell therapy for liver disease: parameters governing the success of using bone marrow mesenchymal stem cells. Gastroenterology 134, 2111-2121 (2008). •• Provides evidence that adoptive mesenchymal stem cell treatment may represent a new therapeutic approach for patients with liver disease.
119. Dai LJ, Li HY, Guan LX, Ritchie G, Zhou JX. The therapeutic potential of bone marrow-derived mesenchymal stem cells on hepatic cirrhosis. Stem Cell Res. 2, 16-25 (2009).
120. Kharaziha P, Hellstrom PM, Noorinayer B et al. Improvement of liver function in liver cirrhosis patients after autologous mesenchymal stem cell injection: a Phase I-II clinical trial. Eur. J. Gastroenterol. Hepatol. 21(10), 1199-1205 (2009).
121. Mohamadnejad M, Alimoghaddam K, Mohyeddin-Bonab M et al. Phase 1 trial of autologous bone marrow mesenchymal stem cell transplantation in patients with decompensated liver cirrhosis. Arch. Iran Med. 10, 459-466 (2007). (Pubitemid 350001896)
122. Wang FS, Zhang JY. Bringing the antiviral therapy home for chronic hepatitis B patients: host immunity influences the efficacy and disease prognosis. Zhonghua Gan Zang Bing Za Zhi 17, 164-166 (2009).
123. Liaw YF. Hepatitis B virus replication and liver disease progression: the impact of antiviral therapy. Antivir. Ther. 11, 669-679 (2006).
124. Lu M, Menne S, Yang D, Xu Y, Roggendorf M. Immunomodulation as an option for the treatment of chronic hepatitis B virus infection: preclinical studies in the woodchuck model. Expert. Opin. Investig. Drugs 16, 787-801 (2007). (Pubitemid 46882354)